FDA Advisory Committee Reviews Bulk Drug Substances for Compounding List

The Food and Drug Administration's Pharmacy Compounding Advisory Committee is currently meeting to evaluate various bulk drug substances. These discussions are critical for deciding which substances will be added to the 503A Bulks List. The committee's determinations will influence the availability and regulation of compounded medications nationwide, affecting both pharmacies and patients.